| Abstrakt: |
A recent report from the University of Florida discusses the management of post-transplant lymphoproliferative disorder (PTLD) associated with the Epstein-Barr Virus (EBV). The usual treatment for PTLD includes reducing immunosuppression and chemotherapy with rituximab. However, if PTLD is refractory to rituximab, limited therapies are available. The report highlights a case of a toddler with refractory EBV-PTLD after a heart transplant who required EBV-directed T-cell therapy. The article aims to provide insights into the clinical presentation, progression, and management of PTLD with EBV-directed T-cell therapy. [Extracted from the article] |
